Phase 2a Study of Baxdrostat in Primary Aldosteronism

2025/07/13 by Adina F. Turcu, Mason W. Freeman, Irina Bancos +12 · 2 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Hormonal Regulation and Hypertension #Adrenal and Paraganglionic Tumors #Eicosanoids and Hypertension Pharmacology

paper · doi:10.1056/nejmc2508629

Abstract

In 15 patients with primary aldosteronism, baxdrostat (a second-generation, nonimidazole aldosterone synthase inhibitor) resolved or reduced the severity of hypertension, excessive aldosterone prod...

Cited by

• Aldosterone synthase inhibitors across the translational spectrum: Mechanistic foundations and emerging clinical applications
• Emerging methods for subtype differentiation in primary aldosteronism

Related

• Primary Aldosteronism: State-of-the-Art Review
• Things We Do for No Reason™: Failing to consider primary aldosteronism in the initial evaluation of hypertension, hypertensive urgency, and hypertensive emergency
• Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
• Comparison of ambulatory blood pressure between patients with primary aldosteronism and other forms of hypertension
• Real-world outcomes of finerenone in primary aldosteronism